2023年2月第30卷第2期Ⅲ期胃癌新辅助化疗中应用DOS方案与SOX方案的效果及安全性分析袁冬冬，吴涛（安阳市肿瘤医院／河南科技大学第四附属医院内科，河南安阳455000）【摘要】目的探讨Ⅲ期胃癌新辅助化疗中应用多西他赛、奥沙利铂联合替吉奥（DOS）方案与奥沙利铂联合替吉奥（SOX）方案的效果及安全性。方法100例行新辅助化疗的Ⅲ期胃癌患者随机分为两组，观察组行DOS方案治疗，对照组行SOX方案治疗，比较两组的化疗效果以及安全性。结果观察组的ORR为48．00％，高于对照组的28．00％（P＜0．05）；两组的DCR比较，差异无统计学意义（94．00％vs．86．00％，P＞0．05）。观察组的R0切除率为88．00％，高于对照组的70．00％（P＜0．05）。两组的化疗不良反应发生率比较，差异无统计学意义（P＞0．05）。结论Ⅲ期胃癌新辅助化疗中应用DOS方案与SOX方案均具有一定的临床疗效，但DOS方案的ORR、R0切除率及安全性更高。【关键词】Ⅲ期胃癌；新辅助化疗；DOS方案；SOX方案中图分类号：R735.2文献标识码：Adoi:10.3969/j.issn.1674-4659.2023.02.0201AnalysisontheEffectsandSafetyofDOSRegimenandSOXRegimenAppliedinNeoadjuvantChemotherapyforStageⅢGastricCancer//YUANDongdong,WUTao(DepartmentofInternalMedicine,AnyangCancerHospital/theFourthAffiliatedHos-pitalofHe'nanUniversityofScienceandTechnology,Anyang455000,China)[Abstract]ObjectiveToexploretheeffectsandsafetyofdocetaxel,oxaliplatincombinedwithtegafur(DOS)regimenandoxaliplatincombinedwithtegafur(SOX)regimenappliedinneoadjuvantchemotherapyforstageⅢgastriccancer.Methods100patientswithstageⅢgastriccancerwhounderwentneoadjuvantchemotherapywererandomlydividedintotwogroups.TheobservationgroupwastreatedwithDOSregimen,andthecontrolgroupwastreatedwithSOXregimen.Thechemotherapyeffectsandsafetywerecomparedbetweenthetwogroups.ResultsTheORRoftheobservationgroupwas48.00%,higherthan28.00%ofthecontrolgroup(P<0.05);NostatisticaldifferencewasfoundintheDCRbetweenthetwogroups(94.00%vs.86.00%,P>0.05).TheR0resectionrateoftheobservationgroupwas88.00%,higherthan70.00%ofthecontrolgroup(P<0.05).Nostatisticaldifferencewasfoundintheincidenceofadversereactionsofchemotherapybetweenthetwogroups(P>0.05).ConclusionsBothDOSregimenan...
